The U.S. Food and Drug Administration (FDA) has approved Grafapex (treosulfan), an injectable chemotherapy, as part of the drug regimen for adults and…
News
PANCREATIC CANCER
Combination treatment shows promise for pancreatic cancer PDAC
Treatment with certepetide in combination with standard therapies led to stable disease in most people with a type of pancreatic cancer known as…
The U.S. Food and Drug Administration (FDA) has approved FoundationOne CDx, Foundation Medicine’s companion diagnostic test to help identify if patients with pediatric low-grade…
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Calquence (acalabrutinib) as a treatment for mantle cell lymphoma (MCL), a rare and…
GYNECOLOGICAL CANCER
Findings can differ in 2 genetic tests guiding ovarian cancer treatment
Discrepancies were identified between two genetic analysis platforms used to detect mutations that guide the treatment of ovarian, fallopian tube, or primary peritoneal cancers in…
Abbvie is teaming up with China-based company Simcere Zaiming to advance the development of SIM0500, Simcere’s experimental treatment for multiple myeloma that’s…
PANCREATIC CANCER
Germany clears pelareorep pancreatic cancer trial continuation
Authorities in Germany have given Oncolytics Biotech the go-ahead to continue enrollment in a Phase 1/2 clinical trial testing the company’s viral therapy pelareorep…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to a novel brain cancer treatment — one designed for malignant gliomas…
GYNECOLOGICAL CANCER
Medicaid expansion can raise demand for gynecologic cancer care
An expansion of Medicaid services in the state of Virginia led within months to more young and middle-aged women of lower income being treated in…
A subcutaneous, or under-the-skin, formulation of Sarclisa (isatuximab) is just as effective as the approved intravenous (into-the-vein) version of the therapy at controlling treatment-resistant…
Recent Posts
- My husband and I aren’t just each other’s caregivers; we’re care partners
- Under-the-skin myeloma therapy shows strong responses in Phase 2 trial
- Trial finds treatment eases PV symptoms despite missing main goal
- The quiet courage of taking a short break as a caregiver
- EU clears Tecvayli as solo option when myeloma returns after first treatment